Cozad Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cozad Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-900	Closed	-$352K	–	435
2025 Q3	$352K	Hold	900	–	–	0.03%	337
2025 Q2	$401K	Hold	900	–	–	0.04%	307
2025 Q1	$436K	Hold	900	–	–	0.04%	286
2024 Q4	$362K	Hold	900	–	–	0.03%	301
2024 Q3	$419K	Hold	900	–	–	0.04%	286
2024 Q2	$422K	Hold	900	–	–	0.04%	277
2024 Q1	$376K	Hold	900	–	–	0.04%	286
2023 Q4	$366K	Hold	900	–	–	0.04%	290
2023 Q3	$313K	Hold	900	–	–	0.04%	293
2023 Q2	$317K	Sell	900 -32	-3%	-$10.8K	0.04%	295
2023 Q1	$294K	Hold	932	–	–	0.04%	300
2022 Q4	$269K	Buy	+932	New	+$284K	0.04%	311
2021 Q2	–	Sell	-5,170	Closed	-$1.11M	–	364
2021 Q1	$1.11M	Buy	5,170 +1,240	+32%	+$272K	0.18%	142
2020 Q4	$929K	Buy	3,930 +420	+12%	+$96.4K	0.17%	147
2020 Q3	$955K	Buy	+3,510	New	+$968K	0.18%	135

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Cozad Asset Management's VRTX Position: Q4 2025 in Review

Cozad Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 900 shares — an estimated $352K sold.

Cozad Asset Management first reported a position in VRTX in Q3 2020 and held it in 15 quarters. The position peaked at $1.11M in Q1 2021. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Cozad Asset Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Cozad Asset Management sold 900 Vertex Pharmaceuticals shares in Q4 2025, an estimated $352K.
Cozad Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 15 quarters.
Cozad Asset Management's Vertex Pharmaceuticals position peaked at $1.11M in Q1 2021.
1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Cozad Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.